|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University Hospital Inselspital, Berne |
|---|---|
| Collaborator: |
University of Bern |
| Information provided by: | University Hospital Inselspital, Berne |
| ClinicalTrials.gov Identifier: | NCT00563940 |
Purpose
Diabetic macular edema is a common complication of ocular diabetes mellitus and can cause blindness. Hypoxygenation of the retina stimulates tissue mediators, especially different subtypes of vascular endothelial growth factor (VEGF). VEGF is responsible for proliferation, extension and increased permeability of the vessels. The aim of our study was to examine the short-term effect of intravitreal bevacizumab (Avastin® 1.25 mg in 0.05 ml) and triamcinolone on visual acuity and central retinal thickness in patients with clinically significant diabetic macular edema (CSME).
| Condition |
|---|
|
Diabetic Macular Edema |
| Study Type: | Observational |
| Study Design: | Case-Only, Prospective |
| Official Title: | Short-Term Effects of Intravitreal Bevacizumab and Trimacinolone in Patients With Diabetic Macular Edema |
| Estimated Enrollment: | 30 |
| Study Start Date: | March 2007 |
| Estimated Study Completion Date: | March 2008 |
| Groups/Cohorts |
|---|
| 1 |
| 2 |
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients with clinical significant macular edema
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Switzerland | |
| Klinik und Poliklinik für Augenheilkunde | |
| Bern, Switzerland | |
| Principal Investigator: | Ute Wolf-Schnurrbusch, MD | University of Bern |
| Study Director: | Sebastian Wolf, MD PhD | University of Bern |
More Information
| Study ID Numbers: | AUG 044/07, KEK E: 29-03-07 |
| Study First Received: | November 26, 2007 |
| Last Updated: | December 5, 2007 |
| ClinicalTrials.gov Identifier: | NCT00563940 History of Changes |
| Health Authority: | Switzerland: Ethikkommission |
|
diabetic macular edema OCT |
|
Antineoplastic Agents Eye Diseases Growth Substances Physiological Effects of Drugs Edema Macular Degeneration Retinal Degeneration Bevacizumab |
Angiogenesis Inhibitors Pharmacologic Actions Macular Edema Signs and Symptoms Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Retinal Diseases |